問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳國興

Recruiting

List

71Cases

2025-01-10 - 2031-05-31

Phase II

Active
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

  • Condition/Disease

    Gastrointestinal Cancer

  • Test Drug

    Injectable

Participate Sites
6Sites

Recruiting6Sites

2025-03-01 - 2030-02-01

Phase III

Active
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

  • Condition/Disease

    Gastric Cancer 、Gastroesophageal Junction Cancer

  • Test Drug

    Frozen Crystal Injection Frozen Crystal Injection Injection Injection Injection Film-Coated Tablets Injection

Participate Sites
5Sites

Recruiting5Sites

2025-05-01 - 2028-07-31

Active
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    N/A

Participate Sites
6Sites

Recruiting6Sites

2025-06-10 - 2033-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

  • Condition/Disease

    Colon Adenocarcinoma、 Rectal Adenocarcinoma

  • Test Drug

    Tablets

Participate Sites
4Sites

Recruiting4Sites

2025-08-01 - 2030-12-31

Phase I

Active
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)

  • Condition/Disease

    Neoplasms

  • Test Drug

    Tablets

Participate Sites
2Sites

Recruiting2Sites

2021-09-01 - 2025-03-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2022-07-01 - 2031-04-21

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-09-01 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-11-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2019-11-01 - 2024-05-13

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

1 2 3 4 5 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB